- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
HeartLung.AI Presents Seven Scientific Talks at ACC.26
The company is the only exhibitor at the cardiovascular conference with this many accepted presentations.
Mar. 19, 2026 at 3:03pm
Got story updates? Submit your updates here. ›
HeartLung.AI announced that it will showcase seven scientific presentations at ACC.26, the American College of Cardiology's 75th Annual Scientific Session & Expo, taking place in New Orleans. HeartLung is the only company in the entire cardiovascular industry exhibit hall that has seven accepted scientific presentations at the ACC Scientific Sessions, covering topics like atrial fibrillation, heart failure, stroke risk, AI-based coronary calcium scoring, plaque hyperdensity, and opportunistic analysis of routine gated and non-gated CT scans.
Why it matters
These accepted presentations reinforce HeartLung's belief that routine CT scans contain more actionable cardiovascular information than is currently being used. Their goal is to help clinicians unlock that information from scans they already have, enabling earlier, more scalable, and more cost-effective prevention of heart disease, heart failure, atrial fibrillation, and stroke.
The details
The seven HeartLung presentations span multiple areas of cardiovascular prevention and opportunistic imaging, including novel AI models for predicting atrial fibrillation and heart failure from coronary artery calcium scans, as well as using AI to analyze chamber volumes, plaque characteristics, and cardiac/pulmonary metrics from both gated and non-gated CT scans. Together, these studies support HeartLung's broader AI-CVD vision of transforming routine CT scans into a scalable platform for earlier cardiovascular detection, better risk stratification, and more personalized prevention.
- HeartLung will present the seven scientific talks at ACC.26, taking place next weekend in New Orleans.
The players
HeartLung.AI
A pioneer in AI-driven preventive imaging, focused on early detection of cardiovascular disease, lung cancer, COPD, osteoporosis, fatty liver disease, and other conditions detectable on CT scans.
Morteza Naghavi, M.D.
The founder of HeartLung.AI.
What they’re saying
“These accepted ACC presentations reinforce our core belief that routine CT scans contain far more actionable cardiovascular information than is being used today. Our goal is to help clinicians unlock that information from scans they already have, enabling earlier, more scalable, and more cost-effective prevention of heart disease, heart failure, atrial fibrillation, and stroke.”
— Morteza Naghavi, M.D., Founder, HeartLung.AI
What’s next
Attendees at ACC.26 are invited to visit HeartLung at Booth 109 to learn more about the company's AI-CVD, AI-CAC, AutoChamber, and related technologies designed to help health systems extract more clinical value from routine CT scans.
The takeaway
HeartLung's multiple scientific presentations at ACC.26 demonstrate its leadership in leveraging AI to unlock the untapped potential of routine CT imaging for earlier and more comprehensive cardiovascular disease detection and prevention.
